Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

From J&J to BMS, New Jersey pharmaceutical companies continue to expand and transform through M&A, leadership shifts and ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

The rally came despite a broader market volatility during the period, largely due to global trade worries over the United States’ imposition of tariffs against its trading partners, with China ...

President Donald Trump says that he was likely to impose tariffs on pharmaceuticals as soon as the end of this month.

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the ...

One study reported 8 live births from 22 women with pathogenic mtDNA variants who underwent mitochondrial donation through pronuclear transfer. None had signs of mitochondrial disease and heteroplasmy ...

(Yicai) July 17 -- Sino Biopharmaceutical said the Chinese drugmaker plans to invest no more than USD951 million to fully ...

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...